SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, phase I/II study to evaluate the efficacy and safety of
SHR-1701 in combination with famitinib in subjects with recurrent/metastatic nasopharyngeal
carcinoma(R/M NPC).